Hollinshead A C, Lee O, Chretien P B, Tarpley J L, Rawls W E, Adam E
Science. 1973 Nov 16;182(4113):713-5. doi: 10.1126/science.182.4113.713.
Serums from tumor-bearing patients, cured patients, and normal subjects were examined for antibodies to the separated complement-fixing reactive components of nonvirion antigens of herpesvirus type 1 and type 2. The occurrence of antibodies to the antigens was similar in serums from tumor-bearing patients and cured patients. Antibodies to the antigens were observed among 21 of 24 (87 percent) cervical cancer cases, 44 of 49 (90 percent) laryngeal cancer cases, 15 of 24 (62 percent) cases of squamous cell carcinomas of the head and neck excluding the larynx, 2 of 24 (8 percent) nonsquamous cell cancer cases, and 3 of 51 (6 percent) normal subjects. By contrast, no differences were found in the titers of neutralizing antibodies to the virus in serums from laryngeal cancer patients and controls. The observations support an etiologic role of herpesviruses in cervical cancer and in laryngeal cancer, and possibly other squamous cell cancers of the head and neck.
对荷瘤患者、治愈患者和正常受试者的血清进行检测，以寻找针对1型和2型疱疹病毒非病毒体抗原中分离出的补体结合反应性成分的抗体。荷瘤患者和治愈患者血清中针对这些抗原的抗体出现情况相似。在24例宫颈癌病例中的21例（87%）、49例喉癌病例中的44例（90%）、24例排除喉部的头颈部鳞状细胞癌病例中的15例（62%）、24例非鳞状细胞癌病例中的2例（8%）以及51例正常受试者中的3例（6%）中观察到了针对这些抗原的抗体。相比之下，喉癌患者血清和对照血清中针对该病毒的中和抗体滴度未发现差异。这些观察结果支持疱疹病毒在宫颈癌、喉癌以及可能在头颈部其他鳞状细胞癌中具有病因学作用。
